Compare · CYCN vs LLY
CYCN vs LLY
Side-by-side comparison of Cyclerion Therapeutics Inc. (CYCN) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYCN and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.12T, about 57632.4x CYCN ($19.4M).
- Over the past year, CYCN is up 57.5% and LLY is up 61.9% - LLY leads by 4.4 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 11 for CYCN).
- LLY has more recent analyst coverage (25 ratings vs 2 for CYCN).
- Company
- Cyclerion Therapeutics Inc.
- Eli Lilly and Company
- Price
- $4.08+0.49%
- $1189.35-3.57%
- Market cap
- $19.4M
- $1.12T
- 1M return
- +19.65%
- -2.65%
- 1Y return
- +57.53%
- +61.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 17
- Recent ratings
- 2
- 25
Cyclerion Therapeutics Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CYCN
- SEC Form 8-K filed by Cyclerion Therapeutics Inc.
- SEC Form 425 filed by Cyclerion Therapeutics Inc.
- SEC Form 8-K filed by Cyclerion Therapeutics Inc.
- Chief Financial Officer Chicko Rhonda M. exercised 25,000 shares at a strike of $2.35, increasing direct ownership by 138,889% to 25,018 units (SEC Form 4)
- Officer Graul Regina Margaret exercised 55,849 shares at a strike of $3.30 and covered exercise/tax liability with 48,629 shares, increasing direct ownership by 7% to 107,523 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Cyclerion Therapeutics Inc.
- SEC Form 425 filed by Cyclerion Therapeutics Inc.
- SEC Form 425 filed by Cyclerion Therapeutics Inc.
- SEC Form 425 filed by Cyclerion Therapeutics Inc.
- SEC Form 10-Q filed by Cyclerion Therapeutics Inc.
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market